Efficacy and safety of oral panobinostat plus subcutaneous bortezomib and oral dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma (PANORAMA 3): an open-label, randomised, phase 2 study
PANORAMA 3 is an open-label, randomized, phase 2 study being done at 71 sites across 21 countries. Patients aged 18 years or older with relapsed or relapsed and refractory multiple myeloma were randomly assigned. The overall response rate was highest in the 20 mg three times weekly and 20 mg twice weekly groups.
